Hypogonadotropic Hypogonadism Clinical Trial
— KASPROfficial title:
Kisspeptin Administration Subcutaneously to Patients With Reproductive Disorders
The goal of this study is to see whether kisspeptin, a naturally occurring hormone, can stimulate the release of other reproductive hormones in women with hypothalamic amenorrhea (HA). The investigators are also examining whether kisspeptin can help women release eggs from their ovaries. Kisspeptin will be administered subcutaneously (SC) for two weeks in a pulsatile fashion. Ultrasound monitoring of ovarian follicular growth and frequent blood sampling (every 10 minutes for up to two hours) will be performed to assess the physiologic response to kisspeptin over time.
Status | Recruiting |
Enrollment | 50 |
Est. completion date | December 2024 |
Est. primary completion date | August 2024 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility | Inclusion Criteria: - Acquired hypogonadotropic hypogonadism (hypothalamic amenorrhea, aka functional hypothalamic amenorrhea) • Confirmed diagnosis by medical provider supported by low sex steroids in the setting of low or inappropriately normal gonadotropins] - Normal blood pressure (systolic BP < 140 mm Hg, diastolic < 90 mm Hg) - Laboratory Studies: - Hemoglobin no less than 0.5 g/dL below the lower limit of the reference range for normal women - Negative serum hCG pregnancy test at screening (additional urine pregnancy test will be conducted prior to drug administration) - Not using hormonal replacement or willing to complete an appropriate washout for that particular medication and method of administration - No current or recent use of a medication that, in the opinion of a study investigator, can modulate the reproductive axis or willing to complete an appropriate washout for that particular medication and method of administration Exclusion Criteria: - Any condition (medical, mental, or behavioral) that, in the opinion of a study investigator, would likely interfere with participation in/completion of the protocol - History of a medication reaction requiring emergency medical care - Excessive alcohol consumption (>10 drinks/week) and/or active use of illicit drugs • Any active use of marijuana will be evaluated by a study medical professional to determine if it may impact study participation. Individuals who regularly use marijuana may be asked to washout as referenced in the medication washout section below - Pregnant or trying to become pregnant - Breast feeding - History of bilateral oophorectomy (ovaries were removed) |
Country | Name | City | State |
---|---|---|---|
United States | Massachusetts General Hospital | Boston | Massachusetts |
Lead Sponsor | Collaborator |
---|---|
Stephanie B. Seminara, MD |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | The proportion of participants that achieve development of a mature follicle or show evidence of ovulation | Mature follicle achievement is defined as evidence of a follicle with maximum diameter =18 mm. Evidence of ovulation is defined as detection of a corpus luteum on ultrasound in combination with elevated progesterone level. | 2 weeks | |
Secondary | Change of luteinizing hormone (LH) pulse amplitude | Difference in LH amplitude on the first day of kisspeptin administration vs the last day of kisspeptin administration | 2 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01438073 -
Elucidating Kisspeptin Physiology by Blocking Kisspeptin Signaling
|
Phase 1 | |
Completed |
NCT01403532 -
Sequential Therapy for Hypogonadotropic Hypogonadism
|
Phase 4 | |
Recruiting |
NCT00456274 -
Baselines in Reproductive Disorders
|
N/A | |
Terminated |
NCT05205837 -
A Randomized, Double-blinded, Clinical, Placebo-controlled Trial on the Effects of Therapy With Letrozole and hUman Choriongonadotropin in Male Hypogonadism Induced by Illicit Use of Anabolic Androgenic Steroids- The LUCAS Trial
|
Phase 4 | |
Completed |
NCT02908074 -
A 6 Month Safety Extension Study of MBGS205
|
Phase 2 | |
Completed |
NCT05752591 -
Hypothalamic-pituitary Dysfunction in Diabetes
|
||
Terminated |
NCT03118479 -
Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)
|
Phase 1 | |
Completed |
NCT02730169 -
Safety and Efficacy of BGS649 in Male Obese Subjects With Hypogonadotropic Hypogonadism
|
Phase 2 | |
Completed |
NCT02110368 -
Bioequivalence Study of Test and Reference Testosterone Topical Gel, 1.62% Metered Pump in Testosterone Deficient Adult Male Subjects Under Fasting Conditions
|
Phase 3 | |
Recruiting |
NCT01601171 -
Genetics of Reproductive Disorders (Including Kallmann Syndrome) and Cleft Lip and/or Palate
|
||
Completed |
NCT01623570 -
Clinical Outcomes in WHO Type I Anovulatory Women Using r-hFSH+r-hLH in a 2:1 Ratio or hMG-HP
|
N/A | |
Terminated |
NCT00328926 -
Luveris® (Lutropin Alfa for Injection) in Women With Hypogonadotropic Hypogonadism (Luteinizing Hormone [LH] Less Than [<] 1.2 International Unit Per Liter [IU/L])
|
Phase 4 | |
Completed |
NCT01438034 -
Kisspeptin in the Evaluation of Delayed Puberty
|
Phase 1 | |
Completed |
NCT04456296 -
A Study of the Effect of Testosterone Replacement Therapy on Blood Pressure in Adult Male Participants With Hypogonadism
|
Phase 4 | |
Recruiting |
NCT00914823 -
Kisspeptin Administration in the Adult
|
Phase 1 | |
Terminated |
NCT01155518 -
Hypogonadism in Young Men With Type 2 Diabetes
|
Phase 2 | |
Completed |
NCT00697814 -
Clomiphene in Males With Prolactinomas and Persistent Hypogonadism
|
Phase 2 | |
Active, not recruiting |
NCT00351416 -
Letrozole Treatment in Normal and GnRH Deficient Women
|
Phase 2/Phase 3 | |
Recruiting |
NCT05971836 -
The Molecular Basis of Inherited Reproductive Disorders
|
||
Recruiting |
NCT02705014 -
Efficacy of Pulsatile GnRH Therapy on Male Patients With Pituitary Stalk Interruption Syndrome
|
N/A |